{"id":391398,"date":"2015-05-21T00:00:00","date_gmt":"2015-05-21T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dbason0215-biopharma-breast-cancer-advanced-metastatic-hr-positive-her2-negative-decision-base-us-2015\/"},"modified":"2026-04-29T23:25:20","modified_gmt":"2026-04-29T23:25:20","slug":"dbason0215-biopharma-breast-cancer-advanced-metastatic-hr-positive-her2-negative-decision-base-us-2015","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dbason0215-biopharma-breast-cancer-advanced-metastatic-hr-positive-her2-negative-decision-base-us-2015\/","title":{"rendered":"Breast Cancer (Advanced\/Metastatic, HR-Positive, HER2-Negative) | Decision Base | US | 2015"},"content":{"rendered":"<p><em>Which Attributes, in the Eyes of Oncologists and Payers, Will Allow Emerging Therapies to Gain Traction in a Market Experiencing Generic Erosion?<\/em><\/p>\n<p>Drug development for advanced\/metastatic, hormone-receptor (HR)-positive, human epidermal growth factor receptor-2 (HER2)-negative breast cancer has gained momentum in recent years. Following its approval in the United States and Europe in mid-2012 and approval in Japan in 2014, the mTOR inhibitor everolimus (Novartis\u2019s Afinitor) in combination with exemestane (Pfizer\u2019s Aromasin, generics) has rapidly become the sales-leading product for this therapy area. Furthermore, a first-in-class CDK4\/6 inhibitor, Pfizer\u2019s palbociclib (Ibrance) received FDA accelerated approval for first-line metastatic, HR-positive, HER2-negative breast cancer in combination with letrozole (Pfizer\u2019s Femara, generics) in February 2015. The backbone of treatment in this population is hormonal therapies, most of which have suffered patent expiry; in addition, most patients in this population respond well to hormonal treatments, meaning improving efficacy with novel agents is difficult. Despite these challenges, the HR-positive, HER2-negative population holds the potential for significant commercial rewards for drug developers, given that it represents more than 70% of diagnosed incident cases of breast cancer.<\/p>\n","protected":false},"template":"","class_list":["post-391398","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-breast-cancer","biopharma-geography-us","biopharma-date-717"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391398","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391398\/revisions"}],"predecessor-version":[{"id":394521,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391398\/revisions\/394521"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391398"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}